We are live on ! Find out more

CPRX

Catalyst Pharmaceutical

CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

73 hedge funds and large institutions have $42.7M invested in Catalyst Pharmaceutical in 2016 Q1 according to their latest regulatory filings, with 9 funds opening new positions, 25 increasing their positions, 18 reducing their positions, and 21 closing their positions.

New

Increased

Maintained

Reduced

Closed

39% more repeat investments, than reductions

Existing positions increased: 25 | Existing positions reduced: 18

14% less funds holding

Funds holding: 85 → 73 (-12)

57% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 21

59% less capital invested

Capital invested by funds: $104M → $42.7M (-$60.8M)

Holders

Holders Change

-12

Holders Change %

-14.12%

% of All Funds

1.95%

Holding in Top 10

–

Holding in Top 10 Change

–

Holding in Top 10 Change %

–

% of All Funds

–

New

Increased

Reduced

Closed

Calls

–

Puts

–

Net Calls

–

Net Calls Change

–

Top Buyers

Rank	Fund	Capital Flow
1	BC Broadfin Capital New York	+$6.23M
2	TCM Tanaka Capital Management New York	+$884K
3	Vanguard Group Malvern, Pennsylvania	+$818K
4	Federated Hermes Pittsburgh, Pennsylvania	+$789K
5	ARTA A.R.T. Advisors New York	+$298K

Top Sellers

Rank	Fund	Capital Flow
1	CCM Consonance Capital Management New York	-$7.08M
2	Franklin Resources San Mateo, California	-$5.21M
3	BBA Baker Bros. Advisors New York	-$4.31M
4	Allianz Asset Management Munich, Germany	-$2.01M
5	PA Perceptive Advisors New York	-$1.24M

#	Name	Holding	Trade Value	Shares Change	Change in Stake
26	WMSA 26 Weiss Multi-Strategy Advisers New York	$143K	–	–	–
27	TA 27 Teachers Advisors New York	$129K	–	–	–
28	28 Charles Schwab San Francisco, California	$126K	–	–	–
29	29 Goldman Sachs New York	$119K	+$115K	+73,958	+265%
30	CS 30 Credit Suisse Zurich, Switzerland	$115K	+$64.7K	+41,700	+74%
31	31 RhumbLine Advisers Boston, Massachusetts	$90K	+$2.21K	+1,425	+2%
32	32 Citigroup New York	$86K	+$79K	+50,896	+224%
33	33 New York State Common Retirement Fund Albany, New York	$80K	–	–	–
34	34 Citadel Advisors Miami, Florida	$74K	-$179K	-115,364	-65%
35	35 Two Sigma Investments New York	$72K	+$95.3K	+61,434	New
36	36 SG Americas Securities New York	$63K	+$84K	+54,123	New
37	PA 37 Perceptive Advisors New York	$60K	-$1.24M	-800,000	-94%
38	38 Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada	$60K	+$7.13K	+4,599	+9%
39	NFA 39 Nationwide Fund Advisors Columbus, Ohio	$57K	–	–	–
40	AL 40 Agran Libbie Santa Monica, California	$56K	+$15.5K	+10,000	+29%
41	AIG 41 American International Group New York	$52K	–	–	–
42	42 VOYA Investment Management Atlanta, Georgia	$50K	–	–	–
43	43 California Public Employees Retirement System Sacramento, California	$48K	–	–	–
44	44 Millennium Management New York	$41K	-$330K	-212,781	-86%
45	45 Susquehanna International Group Bala Cynwyd, Pennsylvania	$38K	+$9.37K	+6,041	+23%
46	46 Commonwealth Equity Services Waltham, Massachusetts	$35K	–	–	–
47	CA 47 Corrado Advisors Ramsey, New Jersey	$32K	+$42K	+27,100	New
48	48 Wells Fargo San Francisco, California	$30K	+$7.12K	+4,591	+21%
49	49 Jacobs Levy Equity Management Florham Park, New Jersey	$30K	+$40K	+25,800	New
50	SO 50 STRS Ohio Columbus, Ohio	$28K	–	–	–

CPRX Hedge Fund Activity: Q1 2016 in Review

73 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q1 2016, worth a combined $42.7M — down 59% from $104M a quarter earlier.

Sellers outnumbered buyers: 21 funds closed out of CPRX and 9 opened new positions — a net loss of 12 holders — while 18 trimmed existing stakes and 25 added.

The largest buyer was Broadfin Capital, adding an estimated $6.23M. The largest seller was Consonance Capital Management, exiting entirely with an estimated $7.08M sold.

73 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q1 2016, down from 85 in Q4 2015.
Funds reported $42.7M of Catalyst Pharmaceutical stock for Q1 2016, down 59% quarter-over-quarter.
9 funds opened new Catalyst Pharmaceutical positions in Q1 2016 and 21 closed out, a net change of -12 holders.
The largest Catalyst Pharmaceutical buyer in Q1 2016 was Broadfin Capital, an estimated $6.23M added.
The largest Catalyst Pharmaceutical seller in Q1 2016 was Consonance Capital Management, an estimated $7.08M sold.

Based on aggregated 13F filings for Q1 2016.

Catalyst Pharmaceutical CPRX